Black seniors more likely to receive low-value acute diagnostic tests
Oct 27, 2023
White patients have a higher rate of low-value screening tests and treatment, including preoperative lab tests and PSA tests.
Thickness of GCIPL, INL of retina reduced in Parkinson’s disease
Aug 24, 2023
“While we are not yet ready to predict whether an individual will develop Parkinson’s, we hope that this method could soon become a pre-screening tool for people at risk of disease,”...
Eligibility limited for anti-β amyloid mAbs in seniors with MCI
Aug 18, 2023
Few older adults with mild cognitive impairment or mild dementia were eligible for lecanemab or aducanumab after applying clinical trial criteria.
Lower frequency of social contact linked to lower total brain volume
Jul 13, 2023
“These results suggest that providing support for people to help them start and maintain their connections to others may be beneficial for preventing brain atrophy and the development of dementia,”...
The high sensitivity and specificity seen for Parkinson’s disease; α-synuclein SAA also can detect prodromal individuals.
Pandemic-linked decline in cancer screening persisted Into 2022
Feb 06, 2023
Low-dose computed tomographic scan rates and mammography rates were lower than expected during March 2021 to February 2022.
Two disease processes contribute to age-related macular degeneration
Jan 13, 2023
Lesions from soft drusen/pigment epithelial detachments have lower mean quantitative autofluorescence, whereas those from subretinal drusenoid deposits have higher.
Study looks at extent of residual lung abnormalities after COVID-19 hospitalization
Dec 02, 2022
The posthospitalization prevalence of residual lung abnormalities was estimated at 11.7% in sensitivity analyses.
Minorities with dementia show lower incidence of amyloid PET positivity
Oct 12, 2022
The authors say that the findings have implications for treating dementia unrelated to amyloid plaques.
New drug for Alzheimer’s disease shows promise in phase 3 trial
Sep 28, 2022
Lecanemab is a monoclonal antibody drug designed to target and help remove Alzheimer’s-associated amyloid plaques in the brain.